GlucoTrack director Paul V. Goode resigns citing potential conflict of interest
GlucoTrack director Paul V. Goode resigned from the board on Sept. 14, 2026, effective immediately. Goode cited a potential conflict of interest tied to talks over duties and obligations under the Lokahi Therapeutics merger agreement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-043389), on September 18, 2026, and is solely responsible for the information contained therein. (C)
GlucoTrack director Paul V. Goode resigned from the board on Sept. 14, 2026, effective immediately. Goode cited a potential conflict of interest tied to talks over duties and obligations under the Lokahi Therapeutics merger agreement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. S.
Securities and Exchange Commission (Ref. ID: 0001493152-26-043389), on September 18, 2026, and is solely responsible for the information contained therein. (C)